Chinese Journal of Antituberculosis ›› 2023, Vol. 45 ›› Issue (3): 311-317.doi: 10.19982/j.issn.1000-6621.20220447
• Review Articles • Previous Articles Next Articles
Zhou Feng1, Li Tongxin1, Yang Song2(), Tang Shenjie3()
Received:
2022-11-09
Online:
2023-03-10
Published:
2023-03-07
Contact:
Yang Song,Tang Shenjie
E-mail:yangsong5@aliyun.com;tangsj1106@vip.sina.com
Supported by:
CLC Number:
Zhou Feng, Li Tongxin, Yang Song, Tang Shenjie. Progress on short-course regimens for the treatment of tuberculosis[J]. Chinese Journal of Antituberculosis, 2023, 45(3): 311-317. doi: 10.19982/j.issn.1000-6621.20220447
Add to citation manager EndNote|Ris|BibTeX
URL: http://www.zgflzz.cn/EN/10.19982/j.issn.1000-6621.20220447
[1] |
Chaisson RE, Frick M, Nahid P. The scientific response to TB-the other deadly global health emergency. Int J Tuberc Lung Dis, 2022, 26(3):186-189. doi:10.5588/ijtld.21.0734.
doi: 10.5588/ijtld.21.0734 pmid: 35197158 |
[2] | World Health Organization.Global tuberculosis report 2020. Geneva: World Health Organization, 2020. |
[3] |
Navarro-Flores A, Fernandez-Chinguel JE, Pacheco-Barrios N, et al. Global morbidity and mortality of central nervous system tuberculosis: a systematic revi ew andmeta-analysis. J Neurol, 2022, 269(7):3482-3494. doi:10.1007/s00415-022-11052-8.
doi: 10.1007/s00415-022-11052-8 pmid: 35288778 |
[4] |
蔡芋晴, 曾惠清, 李琪, 等. 新型冠状病毒肺炎预后临床预测评分研究进展. 中华结核和呼吸杂志, 2022, 45(7):706-711. doi:10.3760/cma.j.cn112147-20211125-00837.
doi: 10.3760/cma.j.cn112147-20211125 |
[5] |
Dheda K, Perumal T, Moultrie H, et al. The intersecting pandemics of tuberculosis and COVID-19: population-level and patient-level impact, clinical presentation, and corrective interventions. Lancet Respir Med, 2022, 10(6):603-622. doi:10.1016/S2213-2600(22)00092-3.
doi: 10.1016/S2213-2600(22)00092-3 pmid: 35338841 |
[6] |
Nie Q, Tao L, Li Y, et al. High-dose gatifloxacin-based shorter treatment regimens for MDR/RR-TB. Int J Infect Dis, 2022, 115:142-148. doi:10.1016/j.ijid.2021.11.037.
doi: 10.1016/j.ijid.2021.11.037 URL |
[7] |
Dorman SE, Nahid P, Kurbatova EV, et al. High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial. Contemp Clin Trials, 2020, 90:105938. doi:10.1016/j.cct.2020.105938.
doi: 10.1016/j.cct.2020.105938 URL |
[8] |
Grace AG, Mittal A, Jain S, et al. Shortened treatment regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis. Cochrane Database Syst Rev, 2019, 12(12): CD012918. doi:10.1002/14651858.CD012918.pub2.
doi: 10.1002/14651858.CD012918.pub2 |
[9] | Silva DR, Mello FCQ, Migliori GB. Shortened tuberculosis treatment regimens: what is new? J Bras Pneumol, 2020, 46(2): e20200009. doi:10.36416/1806-3756/e20200009. |
[10] |
Imperial MZ, Nahid P, Phillips PPJ, et al. A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis. Nat Med, 2018, 24(11):1708-1715. doi:10.1038/s41591-018-0224-2.
doi: 10.1038/s41591-018-0224-2 pmid: 30397355 |
[11] |
Velayutham B, Jawahar MS, Nair D, et al. 4-month moxifloxacin containing regimens in the treatment of patients with sputum-positive pulmonary tuberculosis in South India-a randomised clinical trial. Trop Med Int Health, 2020, 25(4):483-495. doi:10.1111/tmi.13371.
doi: 10.1111/tmi.13371 pmid: 31944502 |
[12] |
Gillespie SH, Crook AM, McHugh TD, et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med, 2014, 371(17):1577-1587. doi:10.1056/NEJMoa1407426.
doi: 10.1056/NEJMoa1407426 URL |
[13] |
Ignatius EH, Swindells S. Are We There Yet? Short-Course Regimens in TB and HIV: From Prevention to Treatment of Latent to XDR TB. Curr HIV/AIDS Rep, 2020, 17(6):589-600. doi:10.1007/s11904-020-00529-8.
doi: 10.1007/s11904-020-00529-8 URL |
[14] |
Naidoo A, Naidoo K, McIlleron H, et al. A Review of Moxifloxacin for the Treatment of Drug-Susceptible Tuberculosis. J Clin Pharmacol, 2017, 57(11):1369-1386. doi:10.1002/jcph.968.
doi: 10.1002/jcph.968 URL |
[15] |
Migliori GB, Besozzi G, Girardi E, et al. Clinical and operational value of the extensively drugresistant tuberculosis definition. Eur Respir J, 2007, 30(4):623-626. doi:10.1183/09031936.00077307.
doi: 10.1183/09031936.00077307 pmid: 17690121 |
[16] |
Reddy KP, Horsburgh CR, Wood R, et al. Shortened Tuberculosis Treatment for People with HIV in South Africa. A Model-based Evaluation and Cost-effectiveness Analysis. Ann Am Thorac Soc, 2020, 17(2):202-211. doi:10.1513/AnnalsATS.201905-418OC.
doi: 10.1513/AnnalsATS.201905-418OC pmid: 31689133 |
[17] |
Svensson EM, Svensson RJ, Te Brake LHM, et al. The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis. Clin Infect Dis, 2018, 67(1):34-41. doi:10.1093/cid/ciy026.
doi: 10.1093/cid/ciy026 pmid: 29917079 |
[18] |
Peloquin C. What is the ‘right’ dose of rifampin?. Int J Tuberc Lung Dis, 2003, 7(1):3-5.
pmid: 12701829 |
[19] |
Tweed CD, Dawson R, Burger DA, et al. Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial. Lancet Respir Med, 2019, 7(12):1048-1058. doi:10.1016/S2213-2600(19)30366-2.
doi: 10.1016/S2213-2600(19)30366-2 pmid: 31732485 |
[20] |
Conde MB, Efron A, Loredo C, et al. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a doubleblind, randomised, controlled phase II trial. Lancet, 2009, 373(9670): 1183-1189. doi:10.1016/S0140-6736(09)60333-0.
doi: 10.1016/S0140-6736(09)60333-0 URL |
[21] |
Milstein M, Lecca L, Peloquin C, et al. Evaluation of high-dose rifampin in patients with new, smear-positive tuberculosis (HIRIF): study protocol for a randomized controlled trial. BMC Infect Dis, 2016, 16(1):453. doi:10.1186/s12879-016-1790-x.
doi: 10.1186/s12879-016-1790-x pmid: 27567500 |
[22] |
Velásquez GE, Brooks MB, Coit JM, et al. Efficacy and Safety of High-Dose Rifampin in Pulmonary Tuberculosis. A Randomized Controlled Trial. Am J Respir Crit Care Med, 2018, 198(5):657-666. doi:10.1164/rccm.201712-2524OC.
doi: 10.1164/rccm.201712-2524OC URL |
[23] |
Dorman SE, Nahid P, Kurbatova EB, et al. Four-month rifapentine regimens withor without moxifloxacin for tuberculosis. N Engl J Med, 2021, 384(18):1705-1718. doi:10.1056/NEJMoa 2033400.
doi: 10.1056/NEJMoa 2033400 URL |
[24] | World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization, 2019. |
[25] |
Pranger AD, van der Werf TS, Kosterink JGW, et al. The Role of Fluoroquinolones in the Treatment of Tuberculosis in 2019. Drugs, 2019, 79(2):161-171. doi:10.1007/s40265-018-1043-y.
doi: 10.1007/s40265-018-1043-y pmid: 30617959 |
[26] |
Dorman SE, Johnson JL, Goldberg S, et al. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med, 2009, 180(3):273-280. doi:10.1164/rccm.200901-0078OC.
doi: 10.1164/rccm.200901-0078OC URL |
[27] | World Health Organization.WHO consolidated guidelines on tuberculosis. Module 4: treatment-drug-susceptible tuberculosis treatment. Geneva: World Health Organization, 2022. |
[28] |
Merle CS, Fielding K, Sow OB, et al. A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med, 2014, 371(17):1588-1598. doi:10.1056/NEJMoa1 315817.
doi: 10.1056/NEJMoa1315817 URL |
[29] |
Jindani A, Harrison TS, Nunn AJ, et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med, 2014, 371(17):1599-1608. doi:10.1056/NEJMoa1314210.
doi: 10.1056/NEJMoa1314210 URL |
[30] |
Turkova A, Wills GH, Wobudeya E, et al. Shorter treatment for non-severe tuberculosis in African and Indian children. N Engl J Med, 2022, 386(10):911-922. doi:10.1056/NEJMoa2104535.
doi: 10.1056/NEJMoa2104535 URL |
[31] |
Van Deun A, Aung KJM, Halim MA, et al. Short, highly effect tive, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med, 2010, 182 (5):684-692. doi:10.1164/rccm.201001-0077OC.
doi: 10.1164/rccm.201001-0077OC URL |
[32] |
Kuaban C, Noeske J, Rieder HL, et al. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. Int J Tuberc Lung Dis, 2015, 19(5):517-524. doi:10.5588/ijtld.14.0535.:517-24.
doi: 10.5588/ijtld.14.0535 pmid: 25868018 |
[33] |
Piubello A, Hassane Harouna S, Souleymane MB, et al. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. Int J Tuberc Lung Dis, 2014, 18 (10):1188-1194. doi:10.5588/ijtld.13.0075.:1188-94.
doi: 10.5588/ijtld.13.0075 pmid: 25216832 |
[34] | World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis. Geneva:World Health Organization, 2016. |
[35] |
Nunn AJ, Phillips PPJ, Meredith SK, et al. A trial of a shorter regimen for rifampin-resistant tuberculosis. N Engl J Med, 2019, 380 (13):1201-1213. doi:10.1056/NEJMoa1811867.
doi: 10.1056/NEJMoa1811867 URL |
[36] |
Padmapriyadarsini C, Vohra V, Bhatnagar A, et al. Bedaquiline, Delamanid, Linezolid and Clofazimine for Treatment of Pre-extensively Drug-Resistant Tuberculosis. Clin Infect Dis, 2022:ciac528. doi:10.1093/cid/ciac528.
doi: 10.1093/cid/ciac528 |
[37] |
Berry C, du Cros P, Fielding K, et al. TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II-III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis. Trials, 2022, 23(1):484. doi:10.1186/s13063-022-06331-8.
doi: 10.1186/s13063-022-06331-8 pmid: 35698158 |
[38] |
Sotgiu G, Centis R, D’Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J, 2012, 40(6):1430-1442. doi:10.1183/09031936.00022912.
doi: 10.1183/09031936.00022912 pmid: 22496332 |
[39] |
Lee M, Mok J, Kim DK, et al. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial. Trials, 2019, 20(1):57. doi:10.1186/s13063-018-3053-1.
doi: 10.1186/s13063-018-3053-1 pmid: 30651149 |
[40] |
Decroo T, Maug AKJ, Hossain MA, et al. Injectables’ key role in rifampicin-resistant tuberculosis shorter treatment regimen outcomes. PLoS One, 2020, 15(8):e0238016. doi:10.1371/journal.pone.0238016.
doi: 10.1371/journal.pone.0238016 URL |
[41] | World Health Organization. Rapid Communication: key changes to the treatment of drug-resistant tuberculosis. Geneva: World Health Organization, 2019. |
[42] | World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva:World Health Organization, 2019. |
[43] |
Ahuja SD, Ashkin D, Avendano M, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med, 2012, 9(8):e1001300. doi:10.1371/journal.pmed.1001300.
doi: 10.1371/journal.pmed.1001300 URL |
[44] |
Bastos ML, Hussain H, Weyer K, et al. Treatment outcomes of patients with multidrug-resistant and extensively drug-resistant tuberculosis according to drug susceptibility testing to first- and second-line drugs: an individual patient data meta-analysis. Clin Infect Dis, 2014, 59(10):1364-1374. doi:10.1093/cid/ciu619.
doi: 10.1093/cid/ciu619 pmid: 25097082 |
[45] |
Ahmad N, Ahuja SD, Akkerman OW, et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data analysis. Lancet, 2018, 392(10150):821-834. doi:10.1016/S0140-6736(18)31644-1.
doi: 10.1016/S0140-6736(18)31644-1 URL |
[46] | World Health Organization. Rapid communication: key changes to the treatment of drug-resistant tuberculosis. Geneva: World Health Organization, 2022. |
[47] |
Ndjeka N, Campbell JR, Meintjes G, et al. Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study. Lancet Infect Dis, 2022, 22(7):1042-1051. doi:10.1016/S1473-3099(21)00811-2.
doi: 10.1016/S1473-3099(21)00811-2 pmid: 35512718 |
[48] |
Conradie F, Diacon AH, Ngubane N, et al. Treatment of highly drug-resistant pulmonary tuberculosis. N Engl J Med, 2020, 382(10): 893-902. doi:10.1056/NEJMoa1901814.
doi: 10.1056/NEJMoa1901814 URL |
[49] |
Esmail A, Oelofse S, Lombard C, et al. An All-Oral 6-Month Regimen for Multidrug-Resistant Tuberculosis: A Multicenter, Randomized Controlled Clinical Trial (the NExT Study). Am J Respir Crit Care Med, 2022, 205(10):1214-1227. doi:10.1164/rccm. 202107-1779OC.
doi: 10.1164/rccm. 202107-1779OC URL |
[50] |
Khan PY, Franke MF, Hewison C, et al. All-oral longer regimens are effective for the management of multidrug-resistant tuberculosis in high-burden settings. Eur Respir J, 2022, 59(1):2004345. doi:10.1183/13993003.04345-2020.
doi: 10.1183/13993003.04345-2020 URL |
[51] |
Conradie F, Bagdasaryan TR, Borisov S, et al. Bedaquiline-Pretomanid-Linezolid Regimens For Drug-Resistant Tuberculosis. N Engl J Med, 2022, 387(9):810-823. doi:10.1056/NEJMoa2119430.
doi: 10.1056/NEJMoa2119430 URL |
[1] | Yang Chao, Wang Jing, Yang Chaohui, Gao Hanqing. Analysis of the epidemiological characteristics and treatment outcomes of pulmonary tuberculosis aged ≥60 years old in Tongzhou District of Beijing, 2016—2022 [J]. Chinese Journal of Antituberculosis, 2024, 46(4): 403-410. |
[2] | Shang Xuetian, Pan Liping. Role of tissue kallikrein family in pathogenesis of microorganism infection [J]. Chinese Journal of Antituberculosis, 2024, 46(2): 239-244. |
[3] | Wang Jiani, Xi Mingxia. Progress in catastrophic health expenditures for tuberculosis [J]. Chinese Journal of Antituberculosis, 2024, 46(1): 112-118. |
[4] | Fu Liang, Deng Guofang. MDR-Chin study analysis: prospects of using all-oral short-course treatment regimens for multidrug-resistant pulmonary tuberculosis in China [J]. Chinese Journal of Antituberculosis, 2024, 46(1): 18-22. |
[5] | Du Yu, Zhang Haipeng, Wang Peng. Research status and application progress of mycobacteria phages [J]. Chinese Journal of Antituberculosis, 2023, 45(9): 897-903. |
[6] | Bi Xiuli, Geng Hong, Jin Jin. The role of myeloid system and CD4+T cells in Mycobacterium tuberculosis infection and immunopathology [J]. Chinese Journal of Antituberculosis, 2023, 45(9): 904-912. |
[7] | Li Yiqi, Liu Yongming, Chen Yaolong, Yang Yinjun, Liu Bei, Wen Fayan, Li Yan. Research progress on animal model of Brucella spondylitis [J]. Chinese Journal of Antituberculosis, 2023, 45(9): 913-920. |
[8] | Wang Hanfei, Zhao Yanlin, Xu Caihong. Research progress of subclinical tuberculosis [J]. Chinese Journal of Antituberculosis, 2023, 45(8): 808-813. |
[9] | Zheng Rui, Zhao Mingrui, Yang Yuanzheng. Meta-analysis of effectiveness and safety of the cycloserine-containing treatment for multidrug-resistant pulmonary tuberculosis in China [J]. Chinese Journal of Antituberculosis, 2023, 45(7): 658-668. |
[10] | Yang Jun, Deng Qiang, Li Junjie, Wang Yurong, Du Jianqiang, Chen Bo, Zhang Lijuan. Research progress on application of local drug delivery and sustained-release system in spinal tuberculosis [J]. Chinese Journal of Antituberculosis, 2023, 45(7): 707-713. |
[11] | Yang Chao, Wang Jing, Tang Guilin, Geng Yang. Analysis of epidemiological characteristics and treatment outcomes of pulmonary tuberculosis patients in floating population in Tongzhou District of Beijing, 2012—2021 [J]. Chinese Journal of Antituberculosis, 2023, 45(6): 594-600. |
[12] | Wang Boning, Li Tao, Chen Wei. Progress on economic burden of patients with drug-resistant tuberculosis [J]. Chinese Journal of Antituberculosis, 2023, 45(6): 607-612. |
[13] | Yang Jun, Deng Qiang, Peng Randong, Li Junjie, Wang Yurong, Yang Haiyun, Du Jianqiang. Establishment and research progress of rabbit model of spinal tuberculosis [J]. Chinese Journal of Antituberculosis, 2023, 45(5): 520-525. |
[14] | Lai Min, Wu Guihui, Chen Hongde, Cheng Yao, Luo Haixia, He Kejing. Clinical characteristics and maternal and infant outcomes of 13 pregnant women with rifampicin resistant and multidrug resistant tuberculosis [J]. Chinese Journal of Antituberculosis, 2023, 45(4): 412-419. |
[15] | Zhang Jingyi, Hu Xingyu, Gao Guangying, Chen Yingchun, Zhang Xin, Deng Qian. The inspiration of bundled payment for chronic diseases in Netherlands and the United States for tuberculosis payment reform in China [J]. Chinese Journal of Antituberculosis, 2023, 45(3): 248-252. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||